Latif is a Principal Research Associate with the Malaria Epidemiology Group who aims to become a vaccine epidemiologist. He is the Principal Investigator in the GlaxoSmithKline sponsored RTS,S/AS01E malaria vaccine phase IV study(EPIMAL-003). He also plays a key role in assisting the efforts of the WHO led RTS,S/AS01E malaria vaccine pilot implementation programme in Malawi through collaboration with various stakeholders.
Latif holds a medical degree from the University of Malawi, College of Medicine and an MSc in Vaccinology from the University of Siena, Italy. He is currently studying an MSc in Epidemiology with the London School of Hygiene and Tropical Medicine distance learning programme. He is highly motivated to contribute to the accelerated reduction of morbidity and mortality of vaccine preventable diseases in Malawi through novel surveillance methods for vaccine programmes. Latif intends to become a vaccine epidemiologist and intends to pursue a PhD in Epidemiology through the Wellcome Trust funded Training Fellowship.
In addition, he also serves on the National Adverse Events Following Immunisation (AEFI) and Adverse Drug Reaction (ADR) Expert Review Committee. The committee is a Technical Working Group that provides support to the National Pharmacovigilance Centre of the Pharmacy Medicines and Poisons Board (PMPB). The committee will report to the Medicines Committee of the PMPB.